

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 November 2019 (21.11.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/222112 A8

(51) International Patent Classification:

A61K 31/553 (2006.01) A61P 35/00 (2006.01)
C07D 513/08 (2006.01)

(21) International Application Number:

PCT/US2019/032053

(22) International Filing Date:

13 May 2019 (13.05.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/671,306 14 May 2018 (14.05.2018) US
62/749,918 24 October 2018 (24.10.2018) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, CA 94404 (US).

(72) Inventors: CHU, Hang; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US). GUER-
RERO, Juan A.; c/o Gilead Sciences, Inc., 333 Lakeside
Drive, Foster City, CA 94404 (US). HURTLEY, Anna
E.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, CA 94404 (US). HWANG, Tae H.; 2575 Victor Ave-
nue, Apt. 249, Glenview, Illinois 60025 (US). JIANG,
Lan; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, CA 94404 (US). KATO, Darryl; c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, CA 94404 (US).
KOBAYASHI, Tetsuya; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US). KNOX, John
E.; 2526 Woodland Place, Emerald Hills, CA 94062 (US).
LAZERWITH, Scott E.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US). LI, Xiaofen;
274 Via Antonio, Thousand Oaks, CA 91320 (US). LIN,
David W.; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, CA 94404 (US). MEDLEY, Jonathan W.; c/
o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City,
CA 94404 (US). MITCHELL, Michael L.; c/o Gilead
Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404
(US). NADUTHAMBI, Devan; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, CA 94404 (US). NEW-
BY, Zachary; 2278 41st Avenue, San Francisco, CA 94116
(US). SQUIRES, Neil H.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US). TSUI, Vick-
ie H.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Fos-
ter City, CA 94404 (US). VENKATARAMANI, Chan-
drasekar; c/o Gilead Sciences, Inc., 333 Lakeside Drive,
Foster City, CA 94404 (US). WATKINS, William J.; c/o
Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA

94404 (US). YANG, Hong; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US).

(74) Agent: YANG, Liuchun et al.; Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, CA 94404 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

12 November 2020 (12.11.2020)

(15) Information about Correction:

see Notice of 12 November 2020 (12.11.2020)

(54) Title: MCL-1 INHIBITORS

(57) Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

WO 2019/222112 A8